Chang-Xin Shi

Chang-Xin Shi

Auto-generated profile, based on publicly available information

Chang-Xin Shi

Department of Medicine, Division of Hematology/Oncology, Mayo Clinic, Scottsdale, Arizona

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2023 in Blood Cancer Discovery
Verified
Journal Article
Open access
PDF file
SWSeth J. Welsh
Seth J. Welsh
BBBenjamin G. Barwick
Benjamin G. Barwick
EMErin W. Meermeier
Erin W. Meermeier
DRDaniel L. Riggs
Daniel L. Riggs
CSChang-Xin Shi
Chang-Xin Shi
PBP. Leif Bergsagel
P. Leif Bergsagel
Multiple myeloma (MM) is a malignancy that is often driven by MYC and that is sustained by IRF4, which are upregulated by super-enhancers. IKZF1 and IKZF3 bind to super-enhancers and can be degraded using immunomodulatory imide drugs (IMiD). Successful IMiD responses downregulate MYC and IRF4; however, this fails in IMiD-resistant cells. MYC and IRF4 downregulation can also be achieved in IMiD-resistant tumors using inhibitors of BET and EP300 transcriptional coactivator proteins; however, in vivo these drugs have a narrow therapeutic window. By combining IMiDs with EP300 inhibition, we demonstrate greater downregulation of MYC and IRF4, synergistic killing of myeloma in vitro and in vivo, and an increased therapeutic window. Interestingly, this potent combination failed where MYC and IRF4 expression was maintained by high levels of the AP-1 factor BATF. Our results identify an effective drug combination and a previously unrecognized mechanism of IMiD resistance. Significance: These results highlight the dependence of MM on IKZF1-bound super-enhancers, which can be effectively targeted by a potent therapeutic combination pairing IMiD-mediated degradation of IKZF1 and IKZF3 with EP300 inhibition. They also identify AP-1 factors as an unrecognized mechanism of IMiD resistance in MM. See related article by Neri, Barwick, et al., p. 56. See related commentary by Yun and Cleveland, p. 5. This article is featured in Selected Articles from This Issue, p. 4

3 December 2015 in Blood
Verified
Journal Article
Open access
YZYuan Xiao Zhu
Yuan Xiao Zhu
CSChang-Xin Shi
Chang-Xin Shi
PJPatrick Jedlowski
Patrick Jedlowski
KKK. Martin Kortüm
K. Martin Kortüm
LBLaura Ann Bruins
Laura Ann Bruins
ASA. Keith Stewart
A. Keith Stewart
Introduction: Partial loss of chromosome arm 1p frequently occurs in multiple myeloma (MM), and is associated with a poor prognosis. Several minimally altered regions on 1p have been identified, including 1p32.3, 1p31.3, 1p22.1-1p21.3, and 1p12. Cytoband 1p12 was deleted in 19% of cases, and this deletion was associated with shorter overall survival (OS) in univariate analysis. The target of homozygous deletion 1p12 was FAM46C. In addition, mutations of FAM46C were identified in 3.4% to 13% of primary MM tumors and 25% of 16 human myeloma cell lines (HMCLs), implying its potential pathogenic relevance. In other work we have suggested that FAM46C mutation is a progression event and have shown that it is rarely seen in newly diagnosed del17 patients, inferring some overlap in function. However, there is no published functional annotation of FAM46C and its role in MM remains unknown. In the present study, we aimed to identify the biological role of FAM46C in myeloma cells. Materials/Method: The expression of FAM46C in HMCLs was analyzed by western blot. Lentiviral constructs expressing wild type and mutated FAM46C were generated and transduced into HMCLs, followed by cell viability assay and cell cycle analysis. Cells were harvested and processed to measure gene expression and cell signaling changes after introduction of FAM46C by mRNAseq, pathway analysis and immunoblotting assay. Results: The expression of FAM46C protein is generally low in most HMCLs. Introduction of wild type FAM46C in HMCLs induced a substantial cell growth inhibition and apoptosis, especially in two HMCLs including MM1.S and KMS11. Cell viability of KMS11 and MM1.S was reduced by 50% to 80% at day 6 after introduction of FAM46C, compared to 0-30% growth retardation detected in HMCLs and non-myeloma cell lines that do not carry FAM46C deletion. We identified 88 genes whose mRNA expression was significantly altered after enforced expression of FAM46C in MM1.S cells. Pathway analysis revealed that FAM46C-regulated genes are enriched in the canonical pathways associated with unfolded protein response, cell cycle control and DNA damage repair. Critical MM genes that are downregulated by FAM46C expression include IRF4 and MYC, which are also downstream targets of immunomodulatory drugs (IMiDs). Consistently, some HMCLs such as KMS11 and OPM2 show an enhanced sensitivity to lenalidomide after introduction of FAM46C. Next, lentiviral constructs expressing various FAM46C mutants were generated in order to understand the consequence of FAM46C mutation. The mutant constructs mimic mutations identified in MM patients or HMCLs. Those mutants and wild type FAM46C were transduced and tested together in MM1.S cells. We found that three published misssense mutations, one frame-shift mutation and deletion of the sequence between aa172 and aa186 of FAM46C (which has been found in previous studies as a hot spot of mutation) all abolished FAM46C-mediated anti-myeloma activity, thus would be expected to confer a MM cell survival advantage. Conclusion: Our data demonstrated that enforced FAM46C expression in myeloma cells induced myeloma growth inhibition and apoptosis. Mutations in FAM46C and TP53 in newly diagnosed patients seem mutually exclusive but not in relapsed patients from our patients sequencing studies, suggesting it may associate with disease progression. Together, these studies suggest that FAM46C may function as a tumor suppressor in myeloma. We also found that published mutations of FAM46C confer a survival advantage to MM cells, and that FAM46C overexpression downregulates IRF4 and MYC and is thus associated with loss of myeloma cell survival.

8 January 2024
Verified
Other
Open access
SWSeth J. Welsh
Seth J. Welsh
BBBenjamin G. Barwick
Benjamin G. Barwick
EMErin W. Meermeier
Erin W. Meermeier
DRDaniel L. Riggs
Daniel L. Riggs
CSChang-Xin Shi
Chang-Xin Shi
PBP. Leif Bergsagel
P. Leif Bergsagel
Supplementary Table 2 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma

25 January 2024
Verified
Other
Open access
SWSeth J. Welsh
Seth J. Welsh
BBBenjamin G. Barwick
Benjamin G. Barwick
EMErin W. Meermeier
Erin W. Meermeier
DRDaniel L. Riggs
Daniel L. Riggs
CSChang-Xin Shi
Chang-Xin Shi
PBP. Leif Bergsagel
P. Leif Bergsagel
Supplementary Data 2 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma

25 January 2024
Verified
Other
Open access
SWSeth J. Welsh
Seth J. Welsh
BBBenjamin G. Barwick
Benjamin G. Barwick
EMErin W. Meermeier
Erin W. Meermeier
DRDaniel L. Riggs
Daniel L. Riggs
CSChang-Xin Shi
Chang-Xin Shi
PBP. Leif Bergsagel
P. Leif Bergsagel
GSEA of genes associated with BATF expression in CoMMpass

25 January 2024
Verified
Other
Open access
SWSeth J. Welsh
Seth J. Welsh
BBBenjamin G. Barwick
Benjamin G. Barwick
EMErin W. Meermeier
Erin W. Meermeier
DRDaniel L. Riggs
Daniel L. Riggs
CSChang-Xin Shi
Chang-Xin Shi
PBP. Leif Bergsagel
P. Leif Bergsagel
Supplementary Figures 1-11, which support data and conclusions provided in the main figures